Association between the casein kinase I epsilon gene region and subjective response to D-amphetamine

Neuropsychopharmacology

Volumn 31, Issue 5, 2006, Pages 1056-1063

  Veenstra VanderWeele, Jeremy ^a   Qaadir, Asfia ^b   Palmer, Abraham A ^b   Cook Jr , Edwin H ^a   De Wit, Harriet ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Amphetamine; Association; Pharmacogenetic; Stimulant; Substance abuse; Translational

Indexed keywords

CASEIN KINASE IEPSILON; DEXAMPHETAMINE; PHOSPHOPROTEIN DARPP 32; PLACEBO;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHROMOSOME 15; CONTROLLED STUDY; CSNKI E GENE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFECTS QUESTIONNAIRE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE; GENE DOSAGE; GENE EXPRESSION; GENE FREQUENCY; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LOW DRUG DOSE; MALE; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOSTIMULATION; QUESTIONNAIRE; REPEATED MEASURES ANALYSIS OF VARIANCE; SECOND MESSENGER; SINGLE NUCLEOTIDE POLYMORPHISM; STIMULATION;

ADOLESCENT; ADULT; ANIMALS; BRAIN; BRAIN CHEMISTRY; CASEIN KINASE IEPSILON; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DEXTROAMPHETAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; GENE FREQUENCY; HUMANS; MALE; MICE; MODELS, ANIMAL; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; QUESTIONNAIRES;

EID: 33646153300     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300936     Document Type: Article

References (48)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association Press Inc.: Washington, DC.
2. Andretic R, Chaney S, Hirsh J (1999). Requirement of circadian genes for cocaine sensitization in Drosophila. Science 285: 1066-1068.
3. Barrett JC, Fry B, Maller J, Daly MJ (2005). HaploView: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
4. Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR et al (2004). Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 101: 5099-5104.
5. Brauer LH, de Wit H (1996). Subjective responses to D-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biol Psychiatry 39: 26-32.
6. Chait LD (1993). Factors influencing the reinforcing and subjective effects of D-amphetamine in humans. Behav Pharmacol 4: 191-199.
7. Chester EJ, Lu L, Shou S, Qu Y, Gu J, Wang J et al (2005). Complex trait analysis of gene expression uncovers polygenic and pleiotropic networks that modulate nervous system function. Nat Genet 37: 233-242.
8. Cubells JF, Kranzler HR, McCance-Katz E, Anderson GM, Malison RT, Price LH et al (2000). A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia. Mol Psychiatry 5: 56-63.
9. de Wit H, Uhlenhuth EH, Johanson CE (1986). Individual differences in the reinforcing and subjective effects of amphetamine and diazepam. Drug Alcohol Depend 16: 341-360.
10. Derogatis L (1983). SCLR-90-R. Administration, Scoring and Procedures Manual-II for the Revised Version and Other Instruments of the Psychopathology Rating Series. Clinical Psychometric Research: Towson, MD.
11. Desdouits F, Siciliano JC, Greengard P, Girault JA (1995). Dopamine- and cAMP-regulated phosphoprotein DARPP-32: phosphorylation of Ser-137 by casein kinase I inhibits dephosphorylation of Thr-34 by calcineurin. Proc Natl Acad Sci USA 92: 2682-2685.
12. Foltin RW, Fischman MW (1991). Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend 28: 3-48.
13. Gabbay FH (2003). Variations in affect following amphetamine and placebo: markers of stimulant drug preference. Exp Clin Psychopharmacol 11: 91-101.
14. Gelernter J, Panhuysen C, Weiss R, Brady K, Hesselbrock V, Rounsaville B et al (2005). Genomewide linkage scan for cocaine dependence and related traits: significant linkages for a cocaine-related trait and cocaine-induced paranoia. Am J Med Genet B 136: 45-52.
15. Gould TD, Manji HK (2005). DARPP-32: a molecular switch at the nexus of reward pathway plasticity. Proc Natl Acad Sci USA 102: 253-254.
16. Greengard P (2001). The neurobiology of slow synaptic transmission. Science 294: 1024-1030.
17. Habas R, Dawid IB (2005). Dishevelled and Wnt signaling: is the nucleus the final frontier? J Biol 4: 2.
18. Hamarman S, Fossella J, Ulger C, Brimacombe M, Dermody J (2004). Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study. J Child Adolesc Psychopharmacol 14: 564-574.
19. Hutchison KE, Wood MD, Swift R (1999). Personality factors moderate subjective and psychophysiological responses to D-amphetamine in humans. Exp Clin Psychopharmacol 7: 493-501.
20. Johanson CE, Uhlenhuth EH (1980). Drug preference and mood in humans: D-amphetamine. Psychopharmacology (Berlin) 71: 275-279.
21. Jones BC, Tarantino LM, Rodriguez LA, Reed CL, McClearn GE, Plomin R et al (1999). Quantitative-trait loci analysis of cocaine-related behaviours and neurochemistry. Pharmacogenetics 9: 607-617.
22. Jones SR, Gainetdinov RR, Wightman RM, Caron MG (1998). Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18: 1979-1986.
23. Kamens HM, Burkhart-Kasch S, McKinnon CS, Li N, Reed C, Phillips TJ (2005). Sensitivity to psychostimulants in mice bred for high and low stimulation to methamphetamine. Genes Brain Behav 4: 110-125.
24. Kloss B, Price JL, Saez L, Blau J, Rothenfluh A, Wesley CS et al (1998). The Drosophila clock gene double-time encodes a protein closely related to human casein kinase Iepsilon. Cell 94: 97-107.
25. Lott DC, Kim SJ, Cook Jr EH, de Wit H (2005). Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology 30: 602-609.
26. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971). Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12: 245-258.
27. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF et al (2003). Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 100: 6186-6191.
28. McNair D, Lorr M, Droppleman L (1971). Profile of Mood States (Manual). Educational and Industrial Testing Service: San Diego.
29. Mitchell SH, Laurent CL, de Wit H (1996). Interaction of expectancy and the pharmacological effects of D-amphetamine: subjective effects and self-administration. Psychopharmacology (Berlin) 125: 371-378.
30. Mitler MM, Hajdukovic R, Erman MK (1993). Treatment of narcolepsy with methamphetamine. Sleep 16: 306-317.
31. Monks SA, Leonardson A, Zhu H, Cundiff P, Pietrusiak P, Edwards S et al (2004). Genetic inheritance of gene expression in human cell lines. Am J Hum Genet 75: 1094-1105.
32. Niculescu III AB, Segal DS, Kuczenski R, Barrett T, Hauger RL, Kelsoe JR (2000). Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol Genom 4: 83-91.
33. Nurnberger Jr JI, Gershon ES, Simmons S, Ebert M, Kessler LR, Dibble ED et al (1982). Behavioral, biochemical and neuroendocrine responses to amphetamine in normal twins and 'well-state' bipolar patients. Psychoneuroendocrinology 7: 163-176.
34. Ogden CA, Rich ME, Schork NJ, Paulus MP, Geyer MA, Lohr JB et al (2004). Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. Mol Psychiatry 9: 1007-1029.
35. Palmer AA, Verbitsky M, Suresh R, Kamens HM, Reed CL, Li N et al (2005). Gene expression differences in mice divergently selected for methamphetamine sensitivity. Mammalian Genome 16: 291-305.
36. Price JL, Blau J, Rothenfluh A, Abodeely M, Kloss B, Young MW (1998). double-time is a novel Drosophila clock gene that regulates PERIOD protein accumulation. Cell 94: 83-95.
37. Pritchard J, Stephens M, Rosenberg N, Donnelly P (2000). Association mapping in structured populations. Am J Hum Genet 67: 170-181.
38. Roman T, Schmitz M, Polanczyk G, Eizirik M, Rohde L, Hutz M (2001). Attention-deficit hyperactivity disorder: a study of association with both the dopamine transporter gene and the dopamine D4 receptor gene. Am J Med Genet (Neuropsychiatric Genet) 105: 471-478.
39. Schadt EE, Monks SA, Drake TA, Lusis AJ, Che N, Colinayo V et al (2003). Genetics of gene expression surveyed in maize, mouse and man. Nature 422: 297-302.
40. Selzer ML (1971). The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Psychiatry 127: 1653-1658.
41. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S (1996). Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35: 409-432.
42. Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, Conlon C et al (2005). Dopamine transporter genotype and methylphenidate dose Response in children with ADHD. Neuropsychopharmacology 30: 1374-1382.
43. Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M et al (2003). Diverse psychotomimetics act through a common signaling pathway. Science 302: 1412-1415.
44. Takano A, Isojima Y, Nagai K (2004a). Identification of mPer1 phosphorylation sites responsible for the nuclear entry. J Biol Chem 279: 32578-32585.
45. Takano A, Uchiyama M, Kajimura N, Mishima K, Inoue Y, Kamei Y et al (2004b). A missense variation in human casein kinase I epsilon gene that induces functional alteration and shows an inverse association with circadian rhythm sleep disorders. Neuropsychopharmacology 29: 1901-1909.
46. The International HapMap Consortium (2003). The international HapMap project. Nature 426: 789-796.
47. Wayne ML, McIntyre LM (2002). Combining mapping and arraying: an approach to candidate gene identification. Proc Natl Acad Sci USA 99: 14903-14906.
48. White TL, Justice AJ, de Wit H (2002). Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav 73: 729-741.